within Pharmacolibrary.Drugs.ATC.D;

model D05BA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 0.3016666666666667,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0023333333333333335,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Methoxsalen (also known as 8-methoxypsoralen) is a furocoumarin derivative used primarily in the treatment of psoriasis, vitiligo, and some cutaneous lymphomas as a photosensitizing agent in combination with UVA (PUVA) therapy. It is still approved and used for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li>F A de Wolff, T V Thomas,Clinical pharmacokinetics of methoxsalen and other psoralens.,Clinical pharmacokinetics,1986<a href='https://pubmed.ncbi.nlm.nih.gov/3512141/'>https://pubmed.ncbi.nlm.nih.gov/3512141/</a></li><li>Youdan Liang, Long Xie, Kai Liu, Yi Cao, Xiaolin Dai, Xian Wang, Jing Lu, Xumin Zhang, Xiaofang Li,Bergapten: A review of its pharmacology, pharmacokinetics, and toxicity.,Phytotherapy research : PTR,2021<a href='https://pubmed.ncbi.nlm.nih.gov/34347307/'>https://pubmed.ncbi.nlm.nih.gov/34347307/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D05BA02;
